Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 191

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 191
---
 BY FINANCE ACTIVITIES                     |     |                |      3 |   |     |                |      - |   |     |                    |  1,394 |   |
| INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS            |     |                | (2,025 | ) |     |                |   (457 | ) |     |                    |    370 |   |
| CASH AND CASH EQUIVALENTS AT THE                            
 BEGINNING OF PERIOD                                         |     |                |  5,293 |   |     |                |  1,186 |   |     |                    |    816 |   |
| CASH AND CASH EQUIVALENTS AT THE                            
 END OF PERIOD                                               |     |                |  3,268 |   |     |                |    729 |   |     |                    |  1,186 |   |

<div align='center'>The accompanying notes are an integral part of
these financial statements.

F-7</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

NOTE 1:– GENERAL

On December
17, 2024, the Company completed the redomicile from the State of Delaware to the State of Nevada (the “Reincorporation. As a result
of the Reincorporation, the Company ceased its business existence as a Delaware corporation and continued its business existence as a
Nevada corporation under the name “Revium Rx.”

In November
2023, the Successor entered into a stock exchange agreement (“Share Exchange”) with Lipovation Ltd, a private Israeli company
engaged in the development of novel pharmaceutical solutions (“Lipovation” or the “Predecessor”). Following the
closing of such agreement on July 23, 2024, the Predecessor became a new wholly owned subsidiary of the Company, and as determined by
the Company’s board of directors. Following the closing of the Share Exchange agreement, the Company’s Board of Directors
determined to discontinue all of the Company’s prior activities and efforts in the development and activation of the clinical decision-making
support system which constituted the business of the Successor prior to the closing of the stock exchange agreement, and to focus on
the development of the acquired LipoVation’s business, refer to Note 3.

| b. | Liquidity and